Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From DexCom, Inc.
Embecta, which recently completed its spin-off from Becton Dickinson, is forging ahead with its insulin injector-based business strategy, GLP-1s be damned.
GLP-1 inhibitors and an ever-shrinking company ecosystem are not issues for the company, according to its CEO.
Insulet’s FDA clearance for its Omnipod 5 App for iPhone will expand its phone-controlled automated insulin delivery system beyond Android users with a full market release in 2024.
Cell and gene therapy is a young biopharma sector approaching adolescence. As more companies transition from R&D to commercialization, has it got the balance right on diversity in senior leadership?
- Monitoring Equipment & Devices
In Vitro Diagnostics
- Glucose Testing
- Other Names / Subsidiaries
- SweetSpot Diabetes Care
- TypeZero Technologies, LLC
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.